AIM ImmunoTech Inc.
$0.49
▲
8.18%
2026-04-21 05:10:01
aimimmuno.com
ASE: AIM
Explore AIM ImmunoTech Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$3.99 M
Current Price
$0.49
52W High / Low
$19.74 / $0.51
Stock P/E
—
Book Value
$-3.19
Dividend Yield
—
ROCE
2638.91%
ROE
251.38%
Face Value
—
EPS
$-8.62
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
19
Beta
1.36
Debt / Equity
-0.5
Current Ratio
0.53
Quick Ratio
0.53
Forward P/E
-0.36
Price / Sales
48.52
Enterprise Value
$6.12 M
EV / EBITDA
-0.53
EV / Revenue
69.53
Rating
None
Target Price
$21.98
EPS Forecast (FY)
—
Pros
- Healthy return on equity.
- Efficient use of capital employed.
- Balance sheet leverage appears manageable.
- Valuation is not stretched on P/E basis.
Cons
- Current ratio suggests tighter short-term liquidity.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Kura Oncology, Inc. | $9.78 | — | $863.87 M | — | -48.86% | -94.82% | $12.49 / $5.45 | $1.98 |
| 2. | CollPlant Biotechnologies Ltd. | $0.37 | — | $5.15 M | — | -141.54% | -1.18% | $4.98 / $0.27 | $0.47 |
| 3. | Jade Biosciences, Inc. | $23.5 | — | $1.13 B | 0% | -34.07% | -89.19% | $100.1 / $6.57 | $6.74 |
| 4. | Assembly Biosciences, Inc. | $28.13 | — | $446.22 M | — | -5.8% | -5.1% | $39.7 / $9.68 | $13.04 |
| 5. | Neumora Therapeutics, Inc. | $2.19 | — | $391.39 M | — | -152.06% | -1.21% | $3.65 / $0.61 | $0.6 |
| 6. | ImmunityBio, Inc. | $8.01 | — | $8.28 B | — | -58.17% | 71.02% | $12.43 / $1.83 | $-0.49 |
| 7. | MindWalk Holdings Corp. | $1.27 | — | $59.32 M | — | -34.42% | -58.82% | $3.25 / $0.4 | $0.23 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0.02 M | 0.03 M | 0.03 M | 0.02 M | 0.04 M | — |
| Operating Profit | -2.95 M | -2.45 M | -2.65 M | -3.62 M | -5.86 M | — |
| Net Profit | -4.17 M | -3.28 M | -2.79 M | -3.71 M | -5.97 M | — |
| EPS in Rs | -0.51 | -0.4 | -0.34 | -0.45 | -0.73 | -5.99 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0.09 M | 0.17 M | 0.2 M | 0.14 M |
| Operating Profit | -11.66 M | -19.77 M | -31.92 M | -19.92 M |
| Net Profit | -13.96 M | -17.32 M | -28.96 M | -19.45 M |
| EPS in Rs | -1.71 | -2.13 | -3.55 | -2.39 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 5.78 M | 8.61 M | 19.38 M | 40.49 M |
| Total Liabilities | 15.56 M | 9.93 M | 9.15 M | 2.02 M |
| Equity | -9.78 M | -1.32 M | 10.23 M | 38.47 M |
| Current Assets | 3.29 M | 4.18 M | 14.56 M | 36.32 M |
| Current Liabilities | 6.22 M | 9.54 M | 8.65 M | 1.36 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -10.96 M | -14.89 M | -21.27 M | -16.11 M |
| Investing CF | 1.85 M | 4.71 M | -0.83 M | 10.99 M |
| Financing CF | 10.39 M | 6.44 M | 0.48 M | 0.08 M |
| Free CF | -11.34 M | -15.44 M | -21.85 M | -16.38 M |
| Capex | -0.38 M | -0.56 M | -0.58 M | -0.27 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -15.84% | 43.26% | — | — |
| Earnings Growth % | 40.2% | -48.94% | — | — |
| Profit Margin % | -10188.24% | -14337.62% | -13790.78% | — |
| Operating Margin % | -11630.59% | -15800% | -14129.79% | — |
| Gross Margin % | 81.76% | 79.21% | 100% | — |
| EBITDA Margin % | -9699.41% | -14219.8% | -13948.23% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2026-02-10 | 1:1.031 |
| 2025-06-12 | 1:0.01 |